To appraise the clinical and cost effectiveness of brigatinib within its marketing authorisation for untreated ALK-positive metastatic non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 1468

Provisional Schedule

Committee meeting 04 November 2020
Expected publication 27 January 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Brigatinib (Takeda)
Others Department of Health
  NHS England
  NHS North East Lincolnshire CCG
  NHS West Essex CCG
  Welsh Government
Patient carer groups ALK Positive UK
  Black Health Agency
  British Lung Foundation
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Comparator companies Novartis (Ceritinib)
  Pfizer (Crizotinib)
  Roche (Alectinib)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
05 March 2020 Invitation to participate
20 January 2020 - 17 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
16 December 2019 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early March 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
13 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late -November 2019. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
25 January 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-August 2019.
02 October 2018 - 30 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
18 April 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance